Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B

Introduction: Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments. This study aimed to evaluate the efficacy and safety of ETV, TDF, and TAF in a real-worl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara Jeong, Hyun Phil Shin, Ha Il Kim
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	chronic hepatitis b entecavir tenofovir treatment outcome safety Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/07c82c69263a4f95bfe7ec1a348cb6dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:07c82c69263a4f95bfe7ec1a348cb6dd
record_format	dspace
spelling	oai:doaj.org-article:07c82c69263a4f95bfe7ec1a348cb6dd2021-12-02T12:40:22ZReal-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B0300-55261423-010010.1159/000519440https://doaj.org/article/07c82c69263a4f95bfe7ec1a348cb6dd2021-11-01T00:00:00Zhttps://www.karger.com/Article/FullText/519440https://doaj.org/toc/0300-5526https://doaj.org/toc/1423-0100Introduction: Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments. This study aimed to evaluate the efficacy and safety of ETV, TDF, and TAF in a real-world clinical setting. Methods: In this retrospective cohort study, a total of 363 CHB patients who were treated with ETV (n = 163), TDF (n = 154), or TAF (n = 46) from July 2007 to September 2019 were enrolled. Results: Median patient age was 51 years and 66.4% of patients were male. Median duration of treatment with ETV, TDF, or TAF was 49.0 months (interquartile range, 27.0–74.0 months). In terms of safety, cholesterol was mildly increased in the ETV and TAF groups and significantly lowered in the TDF group than baseline (p < 0.001). There was no significant difference in liver cirrhosis-related complications among the 3 groups at 48 weeks (p = 0.235). Hepatitis B e antigen seroconversion, complete virological response, and alanine aminotransferase normalization at 48 weeks as measures of treatment efficacy were not significantly different among the 3 groups (p = 0.142, 0.538, and 0.520, respectively). There was also no significant difference in cumulative incidence rate of hepatocellular carcinoma (HCC) between the ETV and TDF groups (p = 0.894). Conclusions: ETV, TDF, and TAF were safe antiviral agents and showed similar antiviral effect for CHB at 48 weeks. Cirrhosis-related complications and annual HCC incidence rates did not differ significantly between the ETV and TDF groups over the 48 week follow-up period.Sara JeongHyun Phil ShinHa Il KimKarger Publishersarticlechronic hepatitis bentecavirtenofovirtreatment outcomesafetySpecialties of internal medicineRC581-951ENIntervirology, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chronic hepatitis b entecavir tenofovir treatment outcome safety Specialties of internal medicine RC581-951
spellingShingle	chronic hepatitis b entecavir tenofovir treatment outcome safety Specialties of internal medicine RC581-951 Sara Jeong Hyun Phil Shin Ha Il Kim Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
description	Introduction: Chronic hepatitis B (CHB) is a major cause of chronic liver diseases and tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), and entecavir (ETV) are recommended as primary treatments. This study aimed to evaluate the efficacy and safety of ETV, TDF, and TAF in a real-world clinical setting. Methods: In this retrospective cohort study, a total of 363 CHB patients who were treated with ETV (n = 163), TDF (n = 154), or TAF (n = 46) from July 2007 to September 2019 were enrolled. Results: Median patient age was 51 years and 66.4% of patients were male. Median duration of treatment with ETV, TDF, or TAF was 49.0 months (interquartile range, 27.0–74.0 months). In terms of safety, cholesterol was mildly increased in the ETV and TAF groups and significantly lowered in the TDF group than baseline (p < 0.001). There was no significant difference in liver cirrhosis-related complications among the 3 groups at 48 weeks (p = 0.235). Hepatitis B e antigen seroconversion, complete virological response, and alanine aminotransferase normalization at 48 weeks as measures of treatment efficacy were not significantly different among the 3 groups (p = 0.142, 0.538, and 0.520, respectively). There was also no significant difference in cumulative incidence rate of hepatocellular carcinoma (HCC) between the ETV and TDF groups (p = 0.894). Conclusions: ETV, TDF, and TAF were safe antiviral agents and showed similar antiviral effect for CHB at 48 weeks. Cirrhosis-related complications and annual HCC incidence rates did not differ significantly between the ETV and TDF groups over the 48 week follow-up period.
format	article
author	Sara Jeong Hyun Phil Shin Ha Il Kim
author_facet	Sara Jeong Hyun Phil Shin Ha Il Kim
author_sort	Sara Jeong
title	Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
title_short	Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
title_full	Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
title_fullStr	Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
title_full_unstemmed	Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
title_sort	real-world single-center comparison of the safety and efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in patients with chronic hepatitis b
publisher	Karger Publishers
publishDate	2021
url	https://doaj.org/article/07c82c69263a4f95bfe7ec1a348cb6dd
work_keys_str_mv	AT sarajeong realworldsinglecentercomparisonofthesafetyandefficacyofentecavirtenofovirdisoproxilfumarateandtenofoviralafenamideinpatientswithchronichepatitisb AT hyunphilshin realworldsinglecentercomparisonofthesafetyandefficacyofentecavirtenofovirdisoproxilfumarateandtenofoviralafenamideinpatientswithchronichepatitisb AT hailkim realworldsinglecentercomparisonofthesafetyandefficacyofentecavirtenofovirdisoproxilfumarateandtenofoviralafenamideinpatientswithchronichepatitisb
_version_	1718393722361610240

Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B

Ejemplares similares